Kaleido Biosciences, Inc. KLDO
OTC PK
| 12/31/2021 | 09/30/2021 | 06/30/2021 | 03/31/2021 | ||
|---|---|---|---|---|---|
| Net Income | -1.28% | 0.20% | -26.25% | -17.86% | |
| Total Depreciation and Amortization | 7.28% | 31.71% | 32.50% | 56.37% | |
| Total Amortization of Deferred Charges | -31.66% | -1.15% | 92.22% | 5.78% | |
| Total Other Non-Cash Items | -42.95% | -54.42% | -19.09% | 52.52% | |
| Change in Net Operating Assets | -85.51% | 172.72% | 273.03% | -241.83% | |
| Cash from Operations | -51.90% | 3.58% | -26.66% | -33.94% | |
| Capital Expenditure | 34.14% | 70.60% | 71.74% | 97.21% | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -- | -- | -- | -- | |
| Cash from Investing | 100.30% | 70.60% | 71.74% | 97.21% | |
| Total Debt Issued | -- | -- | -- | -- | |
| Total Debt Repaid | -- | -- | -- | -- | |
| Issuance of Common Stock | -99.87% | -99.66% | -99.83% | 4,405.45% | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | 100.00% | -- | -- | -- | |
| Cash from Financing | -100.69% | -100.98% | -100.20% | 4,457.76% | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | -106.77% | 1.08% | -219.18% | 364.64% | |